Breast Cancer
Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
Published in Medical Verdicts and Law Weekly, June 21st, 2007
EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, announced the presentation of interim data from the Phase 1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) in combination with Taxol(R) (paclitaxel) in patients with metastatic breast cancer. The study is being conducted at the Duke University Medical Center under a grant from the Susan G. Komen Breast Cancer Foundation. Kimberly L. Blackwell, M.D., Director, Clinical Trials in Breast Cancer at the Duke University Medical Center, and principal investigator presented the data during a podium presentation at the American...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- AARP New York
Long Island Seniors Rally for Rx Affordable Prescription Drugs and Cell Phone Protections - American Medical Informatics Association
AMIA and AHIMA Applaud House Passage of H.R. 1467, the '10,000 Trained by 2010 Act' - American Nurses Association
ANA and NYSNA Condemn Exploitation of Filipino Registered Nurses - Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $75 Million of Convertible Senior Notes - Aneurysm
Rudy Boesch: Still Living Life to the Fullest as a ``Survivor'' in More Ways Than One - ArQule, Inc.
ArQule Announces Offering of Common Stock - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
